Analyst consensus rating
NextCure Analyst Rating: Strong Buy
NXTC is rated Strong Buy by 2 analysts with a $22.50 target. As of 2026-08-21.
Direct answer
NextCure's consensus rating is Strong Buy.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $22.50.
Forecast evidence checked August 21, 2026.
Get free NextCure email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $6.29
- Average price target
- $22.50
- High price target
- $25.00
- Low price target
- $20.00
- Low target gap
- +218%
- Target upside
- +257.7%
- High target gap
- +297.5%
- Target range width
- 79.5%
- Consensus rating
- Strong Buy
- Analysts
- 2
- Evidence date
- August 21, 2026
- Valid through
- August 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for NextCure?
NextCure has a verified Strong Buy consensus. The same dataset has an average price target of $22.50.
How far are NextCure's low and high targets from the recorded price?
The low target implies +218%, while the high target implies +297.5%.
How many analysts are included in NextCure's consensus?
The verified consensus includes 2 analysts.
How is NextCure's target upside or downside calculated?
The average target of $22.50 is divided by the recorded price of $6.29, then one is subtracted to produce +257.7%. This does not guarantee a future return.
When was NextCure's analyst forecast verified?
The data was verified on 2026-08-21. The dataset is valid through 2026-08-28.